The ABCB1 gene, coding for the efflux transporter P-glycoprotein (PGP), is a candidate gene for Alzheimer disease (AD). P-glycoprotein is heavily expressed at the blood—brain barrier, where it mediates the efflux of β-amyloid (Aβ) from the brain. In this study, we investigated a possible association between 2 common ABCB1 polymorphisms, G2677T/A (Ala893Ser/Thr) and C3435T, AD, and cerebrospinal fluid (CSF) levels of Aβ. No strong evidence for association was found.
Chen CJ, Chin JE, Ueda K., et al. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell. 1986;47(3):381-389.
2.
Fromm MFImportance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci. 2004;25(8):423-429.
3.
Demeule M., Regina A., Jodoin J., et al. Drug transport to the brain: key roles for the efflux pump P-glycoprotein in the blood-brain barrier. Vascul Pharmacol. 2002;38(6):339-348.
4.
Lee G., Bendayan R.Functional expression and localization of Pglycoprotein in the central nervous system: relevance to the pathogenesis and treatment of neurological disorders . Pharm Res. 2004;21(8):1313-1330.
5.
Schinkel AH, Wagenaar E., Mol CA, van Deemter L.P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest . 1996;97(11):2517-2524.
6.
Loscher W., Potschka H.Drug resistance in brain diseases and the role of drug efflux transporters . Nat Rev Neurosci. 2005;6(8):591-602.
7.
Lam FC, Liu R., Lu P., et al. beta-Amyloid efflux mediated by p-glycoprotein. J Neurochem. 2001;76(4):1121-1128.
8.
Kuhnke D., Jedlitschky G., Grube M., et al. MDR1-P-Glycoprotein (ABCB1) Mediates transport of Alzheimer’s amyloid-beta peptides-implications for the mechanisms of Abeta clearance at the blood-brain barrier. Brain Pathol. 2007 ;17(4):347-353.
9.
Cirrito JR, Deane R., Fagan AM, et al. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J Clin Invest. 2005;115(11): 3285-3290.
10.
Vogelgesang S., Cascorbi I., Schroeder E., et al. Deposition of Alzheimer’s beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. Pharmacogenetics. 2002 ;12(7):535-541.
11.
Vogelgesang S., Warzok RW, Cascorbi I., et al. The role of P-glycoprotein in cerebral amyloid angiopathy; implications for the early pathogenesis of Alzheimer’s disease. Curr Alzheimer Res. 2004;1(2):121-125.
12.
Bodor M., Kelly EJ, Ho RJCharacterization of the human MDR1 gene. AAPS J. 2005;7(1):E1-E5.
13.
Leschziner GD, Andrew T., Pirmohamed M., Johnson MRABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. Pharmacogenomics J. 2007;7(3):154-179.
14.
Frankfort SV , Doodeman VD, Bakker R., et al. ABCB1 genotypes and haplotypes in patients with dementia and age-matched non-demented control patients. Mol Neurodegener. 2006;1:13.
15.
Tsuang D., Kukull W., Sheppard L., et al. Impact of sample selection on APOE epsilon 4 allele frequency: a comparison of two Alzheimer’s disease samples. J Am Geriatr Soc. 1996;44(6): 704-707.
16.
McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan EMClinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology. 1984;34(7):939-944.
17.
Folstein MF , Folstein SE, McHugh PR‘‘Mini-mental state’’. A practical method for grading the cognitive state of patients for the clinician . J Psychiatr Res. 1975;12(3):189-198.
18.
Peskind ER, Wilkinson CW, Petrie EC, Schellenberg GD, Raskind MA. Increased CSF cortisol in AD is a function of APOE genotype. Neurology. 2001;56(8):1094-1098.
19.
Peskind ER, Li G., Shofer J., et al. Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition. Arch Neurol . 2006;63(7):936-939.
20.
Gaunt TR, Rodriguez S., Zapata C., Day INMIDAS: software for analysis and visualisation of interallelic disequilibrium between multiallelic markers. BMC Bioinformatics. 2006;7:227.
21.
R Development Core Team.R: A language and environment for statistical computing. R Foundation for Statistical Computing. Vienna, Austria. http://www.R-project.org. 2008. Accessed December 5, 2010.
22.
Woodahl EL, Ho RJThe role of MDR1 genetic polymorphisms in interindividual variability in P-glycoprotein expression and function. Curr Drug Metab. 2004;5(1):11-19.
23.
Marzolini C. , Paus E., Buclin T., Kim RBPolymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther . 2004;75(1):13-33.
24.
Shaw LM, Vanderstichele H., Knapik-Czajka M., et al. Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects. Ann Neurol. 2009;65(4):403-413.
25.
Sukhai M., Piquette-Miller M.Regulation of the multidrug resistance genes by stress signals. J Pharm Pharm Sci. 2000;3(2): 268-280.
26.
Su F., Ouyang N., Zhu P., et al. Psychological stress induces chemoresistance in breast cancer by upregulating mdr1. Biochem Biophys Res Commun. 2005;329(3):888-897.
27.
Spudich A., Kilic E., Xing H., et al. Inhibition of multidrug resistance transporter-1 facilitates neuroprotective therapies after focal cerebral ischemia. Nat Neurosci. 2006;9(4):487-488.
